Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs.
Many of recent counterfeit drug incidents — such as the 2012 Avastin incident where counterfeit versions were found in 19 American treatment centers — are sadly not isolated incidents. This white paper shares some insight into the history and geographical reach of counterfeit drugs, as well as prevention and countermeasures.
This white paper will discuss:
- Growing trend and scope of counterfeit drugs
- Impact to patients
- Technological and regulatory countermeasures
- Questions to consider with high-risk shipments